NEO · Neogenomics Inc · Metrics
Market Cap
$2.23B
Shares
128.48M
NEO metrics
74 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$17.32
Market cap
$2.23B
Price action
20 metricsPrice change (1W)
-0.3%
Price change (30D)
+8.7%
Price change (3M)
+55.3%
Price change (6M)
+119.8%
Price change (YTD)
+47.3%
Price change (1Y)
+107.7%
Trailing year
Price change (5Y)
-67.0%
52-week high
$18.64
52-week low
$7.19
Change from 52-week high
-7.1%
Change from 52-week low
+140.9%
Annualized volatility
52.9%
Annualized volatility (3M)
59.0%
Beta
1.1
RSI (14D)
56.0
Price vs SMA 50
+9.2%
Price vs SMA 200
+46.8%
Avg volume (3M)
2.80M
Relative volume
0.4
Average dollar volume
$40.52M
Company
3 metricsSector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
128.48M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
2,059.1×
reciprocal yield 0.0%
EV / EBIT
—
P / sales
2.9×
reciprocal yield 34.4%
P / book
2.8
reciprocal yield 35.3%
FCF yield
-0.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
100.9
reciprocal yield 1.0%
Earnings yield
-2.3%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.7×
reciprocal yield 36.4%
EV / revenue historical average (5Y)
3.9×
reciprocal yield 25.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-07-28
Profitability
9 metricsGross margin
43.9%
Operating margin
-8.9%
Trailing 12 months
Net margin
-6.8%
Gross profit (TTM)
$336.53M
Operating profit (TTM)
−$68.44M
Net income (TTM)
−$51.88M
Trailing 12 months
Diluted EPS (TTM)
$-0.24
FCF margin
-1.0%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+11.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$766.29M
Trailing 12 months
EPS growth YoY
-300.0%
Shares change YoY
+2.3%
Year over year · more shares
Revenue CAGR (3Y)
+12.6%
Revenue CAGR (5Y)
+10.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-6.6%
Return on assets
-3.8%
Debt / equity
—
Current ratio
3.6
EBITDA (TTM)
$1.09M
Free cash flow (TTM)
−$7.36M
Quick ratio
3.3
Interest coverage
-26.5
Net debt / EBITDA
27.0
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$145.54M
Total assets
$1.35B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
$22.05M
Capital expenditures (TTM)
$29.40M
R&D (TTM)
$38.17M
SG&A (TTM)
—
Stock compensation (TTM)
$36.20M
R&D / revenue
5.0%
Stock compensation / revenue
4.7%
Ownership (13F)
3 metrics13F filers
269
13F filer change QoQ
+14
Institutional ownership
120.0%
Short interest
3 metricsShort interest
12.3%
Latest settlement · 9.0 days to cover
Days to cover
9.0d
Short-squeeze score
78 / 100
Insider activity
2 metricsNet insider buying (90D)
−$380,308
Insider-sentiment score
45 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1077183
CUSIP
64049M209
13F (30d)
71 filings
71 filers
Visit website
Investor relations